Tevogen announces significant progress in development of PredicTcell platform

Tevogen (TVGN) announced significant progress in the development of its proprietary PredicTcell platform, designed to accelerate precision immunotherapy development and efficacy through advanced machine learning and transformer-based models. The platform is being developed with the support of Microsoft (MSFT) and Databricks, leveraging their cloud and data technologies to enable scalability and efficiency. The alpha version of PredicTcell was trained on more than 124,000 records using transformer-based architecture and 91,000 records using traditional machine learning architecture. The alpha version of the model delivered recall levels of ~92-97% and a precision range of ~38-43%, serving as a proof-of-concept for AI-driven prediction of immunologically active peptide-T cell receptor interactions.